<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250531066002N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-09-28</date_registration>
      <primary_sponsor>The university of Halabja</primary_sponsor>
      <public_title>Effects of exercise training and dietary supplements (beetroot juice and caffeine) on cardiovascular risk factors in obese men</public_title>
      <acronym></acronym>
      <scientific_title>The combination effects of Beetroots Juice and Caffeine with High-Intensity Interval Training on cardiovascular risk factors in Middle-Aged Obese Men</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84264</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Basic scienece, Randomization description: A stratified randomized block design was implemented, considering peak oxygen consumption and body mass index, with two degrees of fitness and body fat %. Randomly interspersed permuted blocks of sizes 4 and 8 were utilized to reduce predictability. Randomization was conducted at the individual level, with each participant independently assigned to one of four groups. Randomization sequences were produced with the randomizeR program within the R software environment. Within each stratum, groups of 4 or 8 allocations were established. Strict confidentiality was kept through the utilization of sealed, opaque, serially numbered envelopes (SNOSE), which were arranged in a sequence tailored to each stratum. Every envelope included a folded allocation card. Following baseline assessments, recruitment personnel accessed the subsequent envelope in the strata relevant to the participant. The envelopes were stored in a secured cabinet accessible just to the trial coordinator, Blinding description: Participant blinding: Subjects remain uninformed about their group assignment and whether they are getting active supplements, a placebo, or a combination of both. They are aware that the supplements are probably caffeine, beetroot juice, a combination of both, or a placebo. They are also unable to discern their supplement kind from flavor, look, or packaging. Moreover, practitioners engaged in direct engagement with participants (e.g., conducting training sessions, administering supplements, collecting performance data, evaluating results, and analyzing data) remain uninformed about the group type, therefore identifying groups solely by code (Group A, B, C, or D). To preserve blindness, beetroot juice placebos typically consist of nitrate-free beetroot juice or an inert beverage that resembles the color and flavor of beetroot juice. The caffeine and placebo are indistinguishable tablets, frequently opaque. All supplements were made by individuals not participating in the intervention. All participants, irrespective of group affiliation, got two items (a beverage and a pill) every day or prior to exercise.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: beetroot juice: a daily dosage of 70 mL of concentrated beetroot juice (Beet-It Sport Shot 400; James White Ltd, Ashbocking, UK), which contains 400 mg (6.4 mmol) of NO₃⁻ and capsules containing maltodextrin comparable to caffeine capsules. In addition, they perform high-intensity interval training (on a motorized treadmill for 4 × 4-minute intervals at 70-90% of maximum heart rate (HRmax), interspersed with 3 minutes of active recovery) 3 times a week. Intervention 2: Intervention group 2: Caffeine, at a dosage of 6 mg/kg of body weight daily, using pharmaceutical-grade capsules, and a beverage consisting of 1 g of powdered beetroot juice mixed with 1 L of mineral water and lemon juice, akin to the beetroot juice bottle. In addition, they perform high-intensity interval training (on a motorized treadmill for 4 × 4-minute intervals at 70-90% of maximum heart rate (HRmax), interspersed with 3 minutes of active recovery) 3 times a week. Intervention 3: Intervention group 3: caffeine plus beetroot juice; caffeine, a dosage of 6 mg/kg of body weight daily, using pharmaceutical-grade capsules. Moreover, a daily dosage of 70 mL of concentrated beetroot juice (Beet-It Sport Shot 400; James White Ltd, Ashbocking, UK), which contains 400 mg (6.4 mmol) of NO₃⁻, and a placebo capsule similar to a caffeine-containing capsule. In addition, they perform high-intensity interval training (on a motorized treadmill for 4 × 4-minute intervals at 70-90% of maximum heart rate (HRmax), interspersed with 3 minutes of active recovery) 3 times a week. Intervention 4: Intervention group 4: (control-placebo); the placebo group will administer capsules containing maltodextrin comparable to caffeine capsules, along with a beverage consisting of 1 g of powdered beetroot juice mixed with 1 L of mineral water and lemon juice, akin to the beetroot juice bottle, at a specific time.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dara Latif Saifalddin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Research Center University of Halabja, Zanko Street</address>
        <city>Halabja</city>
        <country1>Iraq</country1>
        <zip>46018</zip>
        <telephone>+964 750 107 6597</telephone>
        <email>dara.saifaddin@uoh.edu.iq</email>
        <affiliation>The University of Halabja</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dara Latid Saifalddin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Research Center University of Halabja, Zanko Street</address>
        <city>Halabja</city>
        <country1>Iraq</country1>
        <zip>46018</zip>
        <telephone>+964 750 107 6597</telephone>
        <email>dara.saifaddin@uoh.edu.iq</email>
        <affiliation>University of Halabja</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iraq</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Obese men (BMI ≥30 kg/m²)
Stable weight (±2 kg) for three months
A sedentary lifestyle (&lt;60 minutes/week of structured exercise in the past 6 months)
No history of cardiovascular or metabolic illnesses,
No use of nutritional supplements</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>50 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Chronic illnesses
Tobacco use
Recent nitrate supplementation
Habitual caffeine intake above 200 mg per day</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: beetroot juice: a daily dosage of 70 mL of concentrated beetroot juice (Beet-It Sport Shot 400; James White Ltd, Ashbocking, UK), which contains 400 mg (6.4 mmol) of NO₃⁻ and capsules containing maltodextrin comparable to caffeine capsules. In addition, they perform high-intensity interval training (on a motorized treadmill for 4 × 4-minute intervals at 70-90% of maximum heart rate (HRmax), interspersed with 3 minutes of active recovery) 3 times a week.</i_keyword>
      <i_keyword>Intervention group 2: Caffeine, at a dosage of 6 mg/kg of body weight daily, using pharmaceutical-grade capsules, and a beverage consisting of 1 g of powdered beetroot juice mixed with 1 L of mineral water and lemon juice, akin to the beetroot juice bottle. In addition, they perform high-intensity interval training (on a motorized treadmill for 4 × 4-minute intervals at 70-90% of maximum heart rate (HRmax), interspersed with 3 minutes of active recovery) 3 times a week.</i_keyword>
      <i_keyword>Intervention group 3: caffeine plus beetroot juice; caffeine, a dosage of 6 mg/kg of body weight daily, using pharmaceutical-grade capsules. Moreover, a daily dosage of 70 mL of concentrated beetroot juice (Beet-It Sport Shot 400; James White Ltd, Ashbocking, UK), which contains 400 mg (6.4 mmol) of NO₃⁻, and a placebo capsule similar to a caffeine-containing capsule. In addition, they perform high-intensity interval training (on a motorized treadmill for 4 × 4-minute intervals at 70-90% of maximum heart rate (HRmax), interspersed with 3 minutes of active recovery) 3 times a week.</i_keyword>
      <i_keyword>Intervention group 4: (control-placebo); the placebo group will administer capsules containing maltodextrin comparable to caffeine capsules, along with a beverage consisting of 1 g of powdered beetroot juice mixed with 1 L of mineral water and lemon juice, akin to the beetroot juice bottle, at a specific time.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interleukine-6. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Interleukine-10. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>TNF-α. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>C-reactive protein. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Leptin. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Adiponectin. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Nitric oxide. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Endothelial nitric oxide synthase. Timepoint: Elisa. Method of measurement: Before starting intervention, and 48 hours after the last training session.</prim_outcome>
      <prim_outcome>Oxidized low-density lipoprotein. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Plasma nitrate + nitrite (NOx) concentrations. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Griess assay and immunoassay techniques.</prim_outcome>
      <prim_outcome>Insulin. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Total antioxidant status. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Using a microplate reader on serum samples with a commercial kit.</prim_outcome>
      <prim_outcome>Total oxidant status (TOS). Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Using a microplate reader on serum samples with a commercial kit.</prim_outcome>
      <prim_outcome>Plasma thiobarbituric acid-reactive substances. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Fluorescent thiobarbituric acid (TBA) assay.</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Triglycerides. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Low-density lipoprotein cholesterol. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>High-density lipoprotein cholesterol. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Troponin I. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Troponin T. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Creatine kinase-MB. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Creatine kinase-T. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
      <prim_outcome>Glucose. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Utilizing an auto-analyzer and suitable kits.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body composition. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: Body composition analyzer.</sec_outcome>
      <sec_outcome>VO₂ peak. Timepoint: Before starting intervention, and 48 hours after the last training session. Method of measurement: A graded exercise test on a treadmill.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The university of Halabja</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-24</approval_date>
        <contact_name>The ethical committee Ethical Committee for Human Studies at the University of Halabja</contact_name>
        <contact_address>Research Center University of Halabja, Zanko Street Halabja Halabja Province, Kurdistan Region Iraq</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
